Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Florida Retina Consultants

Neither a doctor nor a teaching hospital

Research payments

$1,077,183

310 payments

Through program year 2025, Florida Retina Consultants is reported as receiving $1,077,183 in research payments, across 310 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $403,838 224
2024 Research $5,791 1
2023 Research $132,411 13
2022 Research $90,236 7
2021 Research $326,234 16
2020 Research $30,376 41
2019 Research $88,298 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $710,836 282 payments
  2. Amgen Inc. $161,706 5 payments
  3. Ocular Therapeutix, Inc. $149,030 12 payments
  4. Roche TCRC, Inc. $40,086 5 payments
  5. AbbVie, Inc. $10,010 2 payments
  6. Allergan Inc. $5,515 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $346,099 158 payments
  2. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $165,169 63 payments
  3. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $149,030 12 payments
  4. ABP 938 Global Phase 3 Study $123,084 3 payments
  5. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $88,171 47 payments
  6. A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy $82,783 4 payments
  7. Oral Treatment of NPDR $40,086 5 payments
  8. ABP 938 Global P3 Study $38,623 2 payments
  9. A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration $28,615 10 payments
  10. Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) $10,010 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record